GM1 Gangliosidosis Type 2a

GM1 gangliosidosis Type 2a, also called late-infantile GM1, is a rare inherited neurological disease caused by severely reduced activity of the enzyme beta-galactosidase (due to two mutated copies of the GLB1 gene). It presents between 7 and 24 months of age with developmental delay or regression, and progressively affects motor skills, language, and neurological function. Unlike Type 1 infantile GM1, Type 2a does not typically cause enlarged organs, cherry-red spots, or coarse facial features. Mean survival is approximately 9 years.

The key differences are severity and multi-organ involvement. Type 1 appears in the first 6 months of life, progresses rapidly, involves the liver, spleen, heart, skeleton, and brain, and is universally fatal before age 3. Type 2a has a later onset (7-24 months), primarily affects the brain and nervous system, does not cause hepatosplenomegaly or cherry-red spots, and has a mean survival of approximately 9 years. The underlying reason is residual enzyme activity: Type 2a patients retain approximately 5-15% of normal beta-galactosidase activity, compared to less than 1-5% in Type 1.

The most common early signs are developmental delay (late achievement of sitting, walking, or first words) and/or active regression of skills the child had previously achieved. Low muscle tone (hypotonia), unsteady movements (ataxia), and eye misalignment (strabismus) are also common early features. Because these signs overlap with many other conditions, diagnosis often takes 1-2 years after symptoms begin.

No. Unlike Type 1 infantile GM1 (where a cherry-red spot is present in approximately 50-60% of patients), Type 2a does not produce a cherry-red spot. The cherry-red spot reflects severe retinal ganglioside accumulation that is characteristic of the most severe, enzyme-deficient cases. In Type 2a, residual enzyme activity is sufficient to prevent this particular accumulation. Absence of a cherry-red spot does NOT exclude GM1 in older toddlers and children.

Diagnosis requires measurement of beta-galactosidase enzyme activity, typically from a blood draw (leukocytes). Reduced activity (approximately 5-15% of normal) confirms the diagnosis. Genetic testing of the GLB1 gene identifies the specific mutations present. Brain MRI may show progressive white matter changes and atrophy, though early MRIs can be near-normal. Diagnosis typically follows a referral to a metabolic genetics specialist.

Mean overall survival is approximately 9 years from birth (based on the largest published historical cohort of French GM1 patients, 2023). Some children with Type 2a survive into their early teens. Survival is influenced by how rapidly the disease progresses (which varies by specific GLB1 mutation and other factors), and significantly by the quality of supportive care, particularly respiratory and nutritional management.

Yes. Type 2a is included in the active treatment pipeline. The Cure GM1 Foundation is advancing the first ICV enzyme replacement therapy for GM1, with FDA regulatory engagement underway. Gene therapy studies (AAV9-GLB1) have published Phase 1/2 results in Type 2 patients. The NAVIGATE Phase 3 trial for nizubaglustat also includes late-infantile disease as part of its target population. We maintain an updated list of active research and trials. See our clinical trials guide.

Yes, through two routes. If a family has one affected child, siblings can be tested for GLB1 mutations (or enzyme activity) very quickly to identify whether they are also affected before symptoms begin. In the future, newborn screening could enable pre-symptomatic identification of all affected infants. Currently no country includes GM1 on its national newborn screening panel, but Cure GM1 Foundation is actively working to change this. GM1 Newborn Screening information.